ArticleTranslational cancer research2022
Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the ERK1/2 and COX-2 pathways.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Retraction · 2024-06-30Concerns/Issues about Image ·
- Retracted
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lovastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, effectively inhibiting cholesterol synthesis. Previous research findings showed that lovastatin markedly suppressed tumor cell proliferation and metastasis and induced apoptosis. The present study aimed to determine the underlying mechanism of the suppressive effect of lovastatin on the growth of human lung cancer cells. Methods: The A549 cell line was treated with different concentrations of lovastatin. Subsequently, cell proliferation and colony formation were analyzed, along with the expression of apoptosis-related proteins (ERK1/2, c-JUN, COX-2, BCL-2, and BAX) by western blotting and immunofluorescence staining. Experimental data were analyzed with SPSS 25.0 and expressed as the mean ± SEM. One-way ANOVA or two-way independent samples Results: The results confirmed that lovastatin suppressed cell viability and reduced the numbers of cell colonies, and a concentration-dependent response was observed with increasing lovastatin concentrations (P<0.05). Accordingly, these suppressive effects were related to decreased protein expression levels of p-ERK1/2/ERK1/2, p-c-JUN/c-JUN, COX-2, and BCL-2 and increased BAX protein expression (P<0.05). Furthermore, we conducted an experimental intervention with low-dose LPS+ATP to stimulate A549 cell growth, and then examined the proliferation and apoptosis of A549 cells after LPS+ATP+50 µM lovastatin intervention. The principal finding of this research was that lovastatin still suppressed A549 cell growth after LPS+ATP stimulation via modulation of ERK1/2, c-JUN, COX-2, BCL-2, and BAX protein levels (P<0.05). Conclusions: Collectively, the findings presented in this study confirmed that lovastatin can inhibit A549 cell proliferation by regulating the ERK1/2 and COX-2 pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.